Endectocidal efficacies of doramectin in naturally parasitized pigs.

The studies reported here were conducted to investigate the effectiveness of doramectin, given intramuscularly at the rate of 300 micrograms kg-1 of bodyweight, in the treatment of naturally acquired porcine nematodosis and acariasis. Twenty pigs demonstrated to be naturally infected with pulmonary and gastrointestinal nematodes were used in one control study, and 22 pigs demonstrated to be naturally parasitized with Sarcoptes scabiei var. suis were used in a second study. In both studies, animals were evenly divided between doramectin plus vehicle and vehicle-treated groups by restricted randomization. In the anthelmintic study, all pigs were necropsied for parasite collection on post-treatment Days 14 and 15. The acaricidal evaluation study was 28 days in duration after treatment, with mite population quantifications on the day of treatment and on post-treatment Days 7, 14, 21 and 28. Doramectin proved 100% effective in the removal of Metastrongylus salmi, M. elongatus, M. pudendotectus, Strongyloides ransomi, Ascaris suum and Oesophagostomum dentatum. Levels of Hyostrongylus rubidus, Ascarops strongylina and Macracanthorhynchus hirudinaceus, as observed at necropsy in the doramectin-treated pigs, were reduced by 99.2%, 99.5% and 62.1%, respectively, as compared with levels seen in the control pigs. In regard to Sarcoptes scabiei var. suis, no live mites were recovered from doramectin-treated pigs during the 7-28 day post-treatment period. In conclusion, doramectin proved highly effective in the treatment of naturally acquired porcine nematodosis and Sarcoptes scabiei var. suis infestation. In addition, all treatments were safe and well tolerated, with no adverse reactions noted in any trial animals.

Effectiveness of the ivermectin sustained-release bolus in the control of bovine nematodosis.

OBJECTIVE: To evaluate the nematocidal effectiveness of the ivermectin sustained-release bolus throughout its 135-day delivery period. DESIGN: Twenty-four naturally infected calves were randomly allocated to 1 of 3 equivalent experimental groups: group-T1 calves were untreated controls, group-T2 calves each received a sustained-release bolus on trial day 0, and group-T3 calves were rendered nematode-free and used at 35-day intervals during the study as tracers. One contaminated pasture was used for all principal calves for the 135-day grazing interval of the study. Calves of groups T1 and T2 were also artificially administered mixed infective nematode larvae at intervals during the grazing period, after which, all calves were confined to concrete for 21 days prior to necropsy. ANIMALS: All calves were approximately 6 months old on trial day 0, weighed from 136 to 216 kg, and were of mixed breeding and sex. PROCEDURE: At intervals during the study, feces from all calves were analyzed for nematode egg counts, and all calves were weighed and examined for bolus retention (T2 calves only). For nematode recovery, all calves were necropsied 21 to 22 days after removal from the contaminated pasture. RESULTS: Parasitic populations of Haemonchus, Ostertagia, Trichostrongylus, Cooperia, Bunostomum, and Oesophagostomum spp were significantly reduced in cattle treated with the ivermectin sustained-release bolus. CONCLUSION: The nematocidal activity of the ivermectin sustained-release bolus proved highly effective, with > 98% efficacy for all nematode species present.

Residual nematocidal effectiveness of ivermectin in cattle.

We assessed the duration of ivermectin persistence by measuring posttreatment nematocidal effectiveness; topical and injectable formulations of ivermectin were evaluated. Thirty-five nematode-free calves were randomly allocated to 1 of 5 treatment groups (7 calves/group). The treatment (Trt) group designations were: Trt 1, nonmedicated; Trt 2, injectable ivermectin administered at the rate of 0.2 mg/kg of body weight on day 0; Trt 3, injectable ivermectin administered at the aforementioned rate, but on day 7; Trt 4, topically administered ivermectin at the rate of 0.5 mg/kg on day 0; and Trt 5, topically administered ivermectin at the aforementioned rate, but on day 7. All calves were subsequently given infective larvae of Haemonchus, Cooperia, Trichostrongylus, and Oesophagostomum spp on day 21. One week later, each calf was additionally administered infective larvae of Dictyocaulus and Ostertagia spp. Trial calves were euthanatized on trial days 49 to 52 for nematode quantitation. On the basis of geometric mean comparisons, total nematode burdens were reduced from control group counts by 98.9 and 86.3% for calves treated on days 7 and 0 with injectable formulations, respectively, and 97.2 and 64.7% for calves treated on days 7 and 0 with pour-on formulations, respectively. Trichostrongylus colubriformis infections were most refractory to the persistent activity of ivermectin, with H placei also proving to be persistence limiting. All treatments were easily administered, and adverse behavioral or tissue reactions were not observed.

Effectiveness of doramectin for treatment of experimentally induced gastrointestinal tract larval nematode infections in calves.

Anthelmintic efficacy of doramectin, a macrocyclic lactone of the avermectin family, was evaluated against larval parasitic nematodes in calves. The investigational product was given SC at a dosage of 0.2 mg/kg of body weight to 10 calves infected 6 days previously with third-stage larvae of the genera Haemonchus, Ostertagia, Cooperia, and Nematodirus. Ten additional calves with identical larval exposure were given saline solution SC also at 6 days after inoculation, and served as the nonmedicated controls. At 14 or 15 days after treatment, the calves were slaughtered in complete replicate for nematode recovery and subsequent quantifications. In comparing nematode numbers at necropsy for the saline- and doramectin-treated groups, nematocidal effectiveness as directed against fourth-stage larvae was: 100% for Haemonchus placei and Cooperia spp, > 99% for Ostertagia ostertagi, and 64.5% for Nematodirus helvetianus. All treatments were easily administered, and adverse behavioral or tissue reactions were not seen to result from doramectin administration.

Employee assistance program treats personal problems.

Though the concept of employee assistance programs (EAPs) is widely accepted throughout business and industry, few hospitals have established similar channels for dealing with workers whose personal problems cause work-related problems. Among the reasons for the health care profession's lack of involvement in this area are: lack of information about costs and benefits of EAPs; the hospital's multidisciplinary environment in which standards of employee competence and behavior are set by persons from many disciplines; hospital working hours; and health care workers' attitudes about their vulnerability to illness. St. Benedict's Hospital, Ogden, UT, however, has confronted the question of how to demonstrate Christian concern for its employees. St. Benedict's EAP, the Helping Hand, which was created in 1979, combines progressive disciplinary action with the opportunity for early intervention in and treatment of employees' personal problems. When a worker with personal problems is referred to the EAP coordinator, he or she is matched with the appropriate community or hospital resource for treatment. Supervisors are trained to identify employee problems and to focus on employee job performance rather than on attempting to diagnose the problem. St. Benedict's records during the program's first three years illustrate the human benefits as well as the cost savings of an EAP. Of 92 hospital employees who took part in the EAP, 72 improved their situations or resolved their problems. The hospital's turnover rates declined from 36 percent to 20 percent, and approximately $40,800 in turnover and replacement costs were saved.